durvalumab + pexastimogene devacirepvec

Durvalumab + pexastimogene devacirepvec is an investigational combination therapy for cancer, specifically studied in refractory or metastatic colorectal cancer. Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Pexastimogene devacirepvec, also known as PexaVec or JX‑594, is an oncolytic vaccinia virus engineered to selectively infect and lyse tumor cells while stimulating systemic anti-tumor immunity through the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF). The combination aims to leverage the immunogenic cell death induced by the oncolytic virus with checkpoint blockade to further activate T-cell mediated anti-cancer effects. This regimen has been evaluated in phase I/II clinical trials for patients with mismatch repair proficient metastatic colorectal cancer who are refractory to standard chemotherapy[1][2][4][6].

Brand names

Imfinzi

Other names

durvalumab + PexaVecdurvalumab + JX-594